Thermo Fisher Scientific Inc. $TMO Stock Sold by Confluence Investment Management LLC

Confluence Investment Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 85,793 shares of the medical research company’s stock after selling 6,988 shares during the period. Confluence Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $57,915,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TMO. QRG Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 48.6% in the 2nd quarter. QRG Capital Management Inc. now owns 36,743 shares of the medical research company’s stock valued at $18,422,000 after acquiring an additional 12,014 shares during the period. Envestnet Portfolio Solutions Inc. boosted its position in Thermo Fisher Scientific by 2.0% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 32,503 shares of the medical research company’s stock valued at $16,286,000 after purchasing an additional 637 shares in the last quarter. Andra AP fonden grew its stake in Thermo Fisher Scientific by 25.3% in the second quarter. Andra AP fonden now owns 72,457 shares of the medical research company’s stock valued at $36,327,000 after purchasing an additional 14,643 shares during the last quarter. Security National Bank of Sioux City Iowa IA raised its holdings in Thermo Fisher Scientific by 25.1% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 7,783 shares of the medical research company’s stock worth $3,902,000 after purchasing an additional 1,560 shares in the last quarter. Finally, Anchor Investment Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 31.2% in the 2nd quarter. Anchor Investment Management LLC now owns 8,232 shares of the medical research company’s stock valued at $4,127,000 after buying an additional 1,960 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMO has been the subject of a number of analyst reports. Barclays increased their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. UBS Group raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Piper Sandler started coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating on the stock. Finally, Scotiabank began coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $628.78.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last ninety days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $13.67 on Thursday, hitting $661.38. 1,001,570 shares of the company were exchanged, compared to its average volume of 2,247,437. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock’s 50 day moving average price is $615.28 and its 200 day moving average price is $532.54. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $683.63. The firm has a market capitalization of $244.54 billion, a P/E ratio of 35.53, a price-to-earnings-growth ratio of 2.84 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.